Press Coverage

Questions Remain about Safety of Parkinson's Psychosis Drug: Report

One of the health highlights mentioned in this update compiled by editors outlines the conclusions from a recent ISMP QuarterWatch report that examined many unanswered questions about the safety and effectiveness of pimavanserin (Nuplazid), a drug used to treat psychosis in Parkinson's patients, and called for stronger warnings on its label.

For the full text, visit U.S. News & World Report online

 

More News

Since the 2021-2022 influenza (flu) vaccine became available in September, the Institute for Safe Medication Practices (ISMP) has received multiple reports of mix-ups. Some patients have consented to a flu vaccine but received one of the COVID-19 vaccines instead, while others have received the flue